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ABSTRACT
RNA interference (RNAi) is a powerful approach to
inhibit human immunodeficiency virus type 1 (HIV-1)
replication. However, HIV-1 can escape from RNAi-
mediated antiviral therapy by selection of mutations
in the targeted sequence. To prevent viral escape,
multiple small interfering RNAs (siRNAs) against
conserved viral sequences should be combined.
Ideally, these RNA inhibitors should be expressed
simultaneously from a single transgene transcript.
In this study, we tested a multiplex microRNA
(miRNA) expression strategy by inserting multiple
effective anti-HIV siRNA sequences in the miRNA
polycistron mir-17-92. Individual anti-HIV miRNAs
that resemble the natural miRNA structures were
optimized by varying the siRNA position in the
hairpin stem to obtain maximal effectiveness
against luciferase reporters and HIV-1. We show
that an antiviral miRNA construct can have a greater
intrinsic inhibitory activity than a conventional short
hairpin (shRNA) construct. When combined in a
polycistron setting, the silencing activity of an
individual miRNA is strongly boosted. We demon-
strate that HIV-1 replication can be efficiently
inhibited by simultaneous expression of four anti-
viral siRNAs from the polycistronic miRNA trans-
cript. These combined results indicate that a
multiplex miRNA strategy may be a promising
therapeutic approach to attack escape-prone viral
pathogens.
INTRODUCTION
RNAi is an evolutionary conserved and sequence-speciﬁc
gene silencing mechanism in eukaryotes (1,2). RNAi can
be induced by double-stranded RNA that is processed
by the RNase III-like enzyme Dicer into 21–25bp siRNAs
(3–5). The siRNA is incorporated into the RNA-induced
silencing complex (RISC) in the cytoplasm and directs
RISC to degrade an mRNA that is perfectly complemen-
tary to one (guide) strand of the siRNA (5).
Cellular miRNAs are the natural inducers of RNAi.
Most miRNAs are synthesized as part of longer primary
RNA transcripts (pri-miRNAs) (6–8). The pri-miRNAs
are cleaved by the nuclear Drosha-DGCR8 complex
to produce miRNA precursors (pre-miRNAs) of  70nt
(9–12). Pre-miRNAs are transported by Exportin-5 to the
cytoplasm, where they are cleaved by Dicer to produce the
miRNA duplex of  22bp. The single-stranded mature
miRNA programs RISC for mRNA cleavage (perfect
complementarity) or translational repression (incomplete
complementarity) (13,14). Several miRNAs are encoded in
genomic clusters that are transcribed as polycistronic
pri-miRNAs, allowing the production of multiple
miRNAs from a single transcription unit (15,16). RNAi
can be induced using RNA polymerase III promoter-
driven shRNA expression vectors that direct siRNA
expression. Another siRNA expression strategy uses a
pre-miRNA backbone that is transcribed by polymerase II
or III (17–20). An optimized pre-miRNA design includes
the single-stranded ﬂanks of the pri-miRNA (21–23).
Currently, RNAi has been employed to inhibit the
replication of a wide range of viruses including HIV-1,
hepatitis C virus (HCV), hepatitis B virus (HBV), dengue
virus, poliovirus, inﬂuenza virus A, coronavirus, herpes-
virus and picornavirus (24,25). For HIV-1, potent inhibi-
tion has been reported with single shRNA and miRNA
expression constructs (17,26–28). However, the therapeu-
tic use of a single inhibitor is limited because of the rapid
emergence of HIV-1 escape mutants (27,29,30). Minor
sequence changes in the target sequence, sometimes even a
single-point mutation, are suﬃcient to overcome RNAi-
mediated inhibition (30), thus demonstrating the exquisite
sequence-speciﬁcity of RNAi.
Strategies to reduce the chance of viral escape include
the simultaneous use of multiple shRNAs in a
*To whom correspondence should be addressed. Tel: +31 20 566 4822; Fax: +31 20 691 6531; Email: b.berkhout@amc.uva.nl
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.combinatorial RNAi approach, which increases the
genetic barrier for viral escape (31,32). Similar strategies
have previously been validated for antisense DNA and
ribozymes (33–35). However, expression of these shRNAs
necessitates multiple expression cassettes and the
construction of rather complex vectors that will not
easily provide equimolar shRNA expression levels.
Furthermore, when the same promoter is reiterated in a
lentiviral vector, recombination occurs with high fre-
quency on the repeated sequences (36). Alternative anti-
escape strategies include the use of a second-generation of
siRNAs that target-speciﬁc escape variants (37), the use of
tandem siRNA transcripts (38), long hairpin RNAs (39)
or the targeting of cellular co-factors that are critically
involved in viral replication (40–44). Another attractive
approach is to express multiple antiviral siRNAs from a
single polycistronic miRNA transcript, such as a natural
genomic miRNA cluster that can be expressed from
an RNA polymerase II promoter. This strategy is of
particular interest for antiviral purposes because miRNA-
like transcripts were shown to be more eﬀective antivirals
than regular shRNAs (17,45). Furthermore, using an
RNA polymerase II promoter will allow lower and
regulated expression, thereby reducing the risk of toxicity
due to oversaturation of the RNAi machinery (46).
In this study, we designed a polycistronic transcript
based on the mir-17-92 backbone to simultaneously
express four anti-HIV siRNAs. To generate this trans-
cript, we ﬁrst constructed individual anti-HIV miRNAs
that resemble the natural pri-miRNA structures. These
hairpins were optimized for viral inhibition by varying the
siRNA position in the hairpin stem. We show that the
expression of individual miRNAs is greatly enhanced in
multiplex hairpin transcripts that are properly processed
into functional miRNAs. HIV-1 replication can be
potently inhibited by simultaneous expression of four
antiviral miRNAs. These combined results indicate that
the multiplex miRNA strategy is a promising therapeutic
approach against escape-prone viral pathogens.
MATERIALS AND METHODS
DNA constructs
The wild-type mir-17-19b polycistron was ampliﬁed from
genomic DNA of 293T cells with primers OncoF1
and OncoR1 and TA-cloned in TOPO2.1 (Invitrogen).
The mir-17-19b polycistron sequence was veriﬁed and
is identical to the sequence in the NCBI database
(NT_009952.14). The TOPO2.1/mir-17-19b construct
was used as a template to generate the antiviral miRNA
constructs. The construction consists of a four-step fusion
PCR as shown in the Supplementary Figure 1. Brieﬂy, the
50-ﬂank of the pri-miRNA was ampliﬁed with a forward
primer encoding a BamHI site and a reverse primer
encoding the HIV-1 sequence at its 30-end (step 1).
Similarly, the 30-ﬂank of the pri-miRNA was ampliﬁed
with a forward primer containing HIV-1 sequences and a
reverse primer encoding BglII and XhoI sites (step 2). Two
complementary oligonucleotides, creating the stem-loop
structure of the antiviral miRNA, were annealed as
described previously (step 3) (32). The partial sequence
similarity between the fragments generated in steps 1, 2
and 3 allowed their fusion by PCR with the outer forward
F1 and reverse R2 primers (step 4), resulting in the
antiviral miRNA. Supplementary Table 1 lists all oligo-
nucleotides used in this study.
PCR ampliﬁcation was performed in a 50ml reaction
containing 1 PCR ampliﬁcation buﬀer (Invitrogen),
1.5–2mM MgCl2 (optimized for each reaction), 25 pmol
of each primer, 0.2mM dNTPs and 2.5 units of AmpliTaq
DNA polymerase (Perkin Elmer Applied Biosystem). The
PCR program was as follows: 958C for 5min, 35 cycles of
2min at 948C, 1.5min at 608C, 2.5min at 728C and a ﬁnal
extension for 8min at 728C. The PCR products were
separated on a 1% agarose gel stained with ethidium
bromide and compared to a standard DNA size marker
(Eurogentec). miRNA PCR products were excised from
gel, puriﬁed with the QIAquick gel extraction kit (Qiagen),
digested with BamHI and XhoI and cloned in the
corresponding sites of pcDNA6.2-GW/EmGFP-miR
(Invitrogen). All miRNA constructs were sequenced with
primers GFPseqF and mirR using the BigDye Terminator
v1.1 Cycle Sequencing Kit (Perkin Elmer Applied
Biosystem).
Multimerization of the individual pri-miRNA units was
performed by digestion of a single miRNA hairpin
construct with BamHI and XhoI and religation into the
BglII/XhoI sites of pcDNA6-miRNA. By repeating this
procedure we obtained constructs expressing diﬀerent
combinations of 1, 2, 3, 4 and 6 pri-miRNAs. The RNA
structures formed by the transcripts were predicted with
the Mfold program (47) at http://frontend.bioinfo.rpi.edu/
applications/mfold/ and found to be similar to the
predicted conformation of the wild-type pri-miRNAs.
The ﬁreﬂy luciferase (FL) reporters containing HIV-1
target sequences pol47 (Luc-A
pol47), pol1 (Luc-B
pol1),
gag5 (Luc-C
gag5), r/t5 (Luc-D
r/t5), ldr9 (Luc-E
ldr9) and
the anti-HIV shRNAs have been described previously
(32). The full-length HIV-1 molecular clone LAI (acces-
sion number AF33819.3) (48) was used to produce wild-
type virus and to study its inhibition by the antiviral
miRNAs and shRNAs.
Cells, DNA transfection andvirus infection
Human embryonic kidney (HEK) 293T cells were grown
as a monolayer in DMEM (Invitrogen) supplemented with
10% fetal calf serum (FCS) (Hybond), minimal essential
medium nonessential amino acids, penicillin (100U/ml)
and streptomycin (100mg/ml) at 378C and 5% CO2. Cells
were trypsinized one day before transfection, resuspended
in DMEM without antibiotics and seeded in 24-well plates
at a density of 1.2 10
5 cells per well. Cells were
co-transfected with the indicated DNA constructs using
Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instructions. One nanogram of pRL
plasmid (Promega) expressing renilla luciferase (RL)
from the CMV promoter was added as an internal control
for cell viability and transfection eﬃciency. All transfec-
tion experiments were controlled for equal DNA input by
adding pBluescript SK- (Promega). Luciferase and renilla
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assay system (Promega) according to the manufacturer’s
instructions. Virus production was determined by measur-
ing the CA-p24 levels in the culture supernatant by ELISA
(Abbott) (49). Subsequently, the cells were lysed to
measure the renilla luciferase activities using the Renilla
Luciferase Assay System (Promega) according to the
manufacturer’s protocol. Transfection experiments were
corrected for between session variations as described
previously (50).
The human T-cell line SupT1 was cultured in 25cm
2
ﬂasks in RPMI 1640 medium supplemented with 10%
FCS, penicillin (100U/ml) and streptomycin (100mg/ml)
at 378C and 5% CO2. 200.000 SupT1 cells were infected
with equal amounts virus (0.5ng CA-p24) produced in
293T cells. When HIV-induced cytopathic eﬀects were
observed, cell and supernatant samples were stored at
 808C. Virus spread was followed by measuring the
CA-p24 levels in the culture supernatant by ELISA.
siRNA detection by Northern blotting
One day before transfection 7.5 10
5 293T cells were
plated in 6-well plates. Cells were transfected with
39–5000ng of the shRNA construct and 2500 or 5000ng
of the miRNA-expression construct using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s
instructions. In all transfection experiments we added
pBluescript SK- (Promega) to obtain identical DNA
concentrations. Total cellular RNA was extracted 2 days
post-transfection with the mirVana miRNA isolation kit
(Ambion) according to the manufacturer’s protocol. For
Northern blot analysis, 15mg total RNA was heated for
5min at 958C before electrophoresis on a 15% denaturing
polyacrylamide gel (precast Novex TBU gel, Invitrogen).
To check for equal sample loading, the gel was stained
with 2mg/ml ethidium bromide in milliQ water for 20min.
Destaining was performed by rinsing the gel three
times with milliQ water for 10min. The ribosomal RNA
(rRNA) bands were visualized under UV light. The RNA
samples were electrotransferred to a positively charged
nylon membrane (Boehringer Mannheim, GmbH,
Mannheim, Germany) and crosslinked to the membrane
using UV light at a wavelength of 254nm (1200mJ 100).
LNA oligonucleotide probes were 50-end labeled with
the kinaseMax kit (Ambion) in the presence of 1ml
[g-
32P]ATP (0.37MBq/ml Amersham Biosciences). To
remove unincorporated nucleotides, the probes were
puriﬁed on Sephadex G-25 spin columns (Amersham
Biosciences) according to the manufacturer’s protocol.
Hybridizations were performed at 428C with labeled LNA
oligonucleotides in 10ml ULTRAhyb hybridization buﬀer
(Ambion) according to the manufacturer’s instructions.
We used the oligonucleotide probes (LNA-positions
underlined): 50-GTGAAGGGGCAGTAGTAAT-30
(pol47 probe), 50-ACAGGAGCAGATGATACAG-30
(pol1 probe), 50-GAAGAAATGATGACAGCAT-30
(gag5 probe), 50-ATGGCAGGAAGAAGCGGAG-30 (r/
t5 probe) and 50-AGATGGGTGCGAGAGCGTC-30
(ldr9 probe). The membranes were washed twice for
5min at 428Ci n2 SSC/0.1% SDS and twice for 15min
at 428C in 0.1 SSC/0.1% SDS. Signals were detected and
quantiﬁed using a phosphorimager (Amersham
Biosciences).
Lentiviral vectorproduction andtransduction
Lentiviral vector plasmids are derived from the construct
pLenti6/V5-Dest (Invitrogen), which we renamed pLV.
The miRNA cassettes, containing a GFP marker, were
inserted into pLV using the Gateway-adapted BLOCK-iT
Lentiviral Pol II miR RNAi Expression System
(Invitrogen) according to the manufacturer’s instructions.
The sequences of all miRNA constructs were veriﬁed
using the primers CMVf and V5r. The miRNA inhibitory
potential was determined by co-transfection with appro-
priate luciferase reporters (results not shown). Lentiviral
vector was produced in 293T cells (2.2 10
6) seeded in
a2 5 c m
2 ﬂask. The next day, medium was replaced with
2.2-ml medium without antibiotics. Subsequently, pLV
vectors expressing a miRNA (2.4mg) were co-transfected
with packaging plasmids pSYNGP (1.5mg) (51), RSV-rev
(0.6mg) and pVSVg (0.8mg) (52) with 16mlo f
Lipofectamine 2000 reagent and 1.5ml Optimem (Gibco
BRL). The second day, medium was replaced with fresh
medium. On the third and fourth day, medium containing
lentiviral vector was harvested and pooled. Cellular debris
was removed by ﬁltration through a FP30/0.45 CA-S ﬁlter
(Schleicher and Schuell MicroScience) and 1-ml aliquots
were stored at  808C. Lentiviral stocks were titrated on
SupT1 and 293T cells to determine the vector titer. SupT1
and 293T cells (1 10
5) were transduced with the pLV
vector expressing an unrelated miRNA N (Invitrogen) or
the antiviral miRNAs A
pol47,B
pol1,C
gag5,D
r/t5,E
ldr9 and
ACDE at a multiplicity of infection (MOI) of 0.15 as
described previously (32). The pLV vector contains the
blasticidin resistance gene, which allows the selection of
transduced cells using 3.5mg/ml blasticidin. The GFP
marker encoded by the miRNA cassette was used to select
GFP+ cells by FACS sorting approximately 10 days
post-transduction.
RESULTS
Designof antiviralmiRNAs
The human mir-17-92 cluster on chromosome 13 encodes
a 1kb pri-miRNA polycistronic transcript with six pre-
miRNAs that produces seven mature miRNAs
(Figure 1A, upper panel) (15). The pre-miR-17 hairpin
encodes two miRNAs, one on the 50 side of the
hairpin (miR-17-5p) and one on the 30 side (miR-17-3p).
We ampliﬁed the sequences encoding the ﬁrst ﬁve pri-
miRNAs from the mir-17-92 polycistron and cloned it
under the control of the cytomegalovirus (CMV) immedi-
ate early promoter (Figure 1A, lower panel). We
subcloned each individual pre-miRNA with at least
40-nt ﬂanks on each side of the hairpin and systematically
replaced the mature miRNA sequences with antiviral
sequences as explained in detail in the Supplementary
Figure 1. The original miRNA names were replaced with
letters A-E and we inserted 19- to 24-nt antiviral sequences
against ﬁve HIV-1 genes (Figure 1B, upper panel).
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which we successfully raised potent shRNA inhibitors
(32). We set out to combine 2, 3, 4 or 5 antiviral miRNAs,
which will eventually result in an antiviral pri-miRNA
polycistron (Figure 1B, lower panel).
We ﬁrst determined if we could produce an optimal
antiviral miRNA construct by varying the position and
length of the anti-HIV sequence. For the initial experi-
ments we chose miRNAs miR-20 and miR-19b (D
wt and
E
wt) because they contain the smallest number of bulges
and thus most resemble the original shRNA structure
(Figure 2). The original mature miRNA and the antiviral
miRNA strand are boxed. We modiﬁed the passenger
strand of the basepaired stem to mimic structural features
(mismatches, bulges and thermodynamic stability) of the
natural pre-miRNA. We constructed a series of antiviral
miRNAs with the eﬀective r/t5 and ldr9 siRNAs in the
D
wt backbone, which produces the antiviral guide strand
from the 50 side of the hairpin duplex. The 19-nt antiviral
siRNAs were positioned either at the 50 (D
r/t5-190
and
D
ldr9-190
)o r3 0-end (D
r/t5-190
and D
ldr9-190
) of the original
miRNA sequence (Figure 2, upper panel). Additional
constructs were made in which we extended the antiviral
siRNAs at the 30-end to 23-nt, which is the actual size of
the wild-type mature miRNA (D
r/t5-23 and D
ldr9-23)
(Figure 2, Table 1). We repeated this strategy for the
r/t5 inhibitor in the E
wt hairpin, which produces the
antiviral guide strand from the 30 side of the hairpin stem
(Figure 2, lower panel). We designed a similar set of
constructs in which the 19-nt r/t5 siRNA was positioned
at the 50 (E
r/t5-190
)o r3 0-end (E
r/t5-190
) of the wild-type
miRNA and an extended 23-nt version (E
r/t5-23).
Activity ofthe antiviralmiRNAs
To determine the inhibitory activity of the miRNA
constructs, we co-transfected 293T cells with the inhibitors
and luciferase reporter constructs containing either the
50-nt r/t5 target (Luc-D
r/t5 and Luc-E
r/t5) or the 50-nt ldr9
target (Luc-D
ldr9). A plasmid encoding renilla luciferase
(pRL) was included to correct for transfection variation
and to monitor for cell viability that may be aﬀected by
oﬀ-target eﬀects of the modiﬁed miRNAs and/or the
antiviral siRNAs. Fireﬂy and renilla luciferase expression
was measured 48h post-transfection. Fireﬂy luciferase
expression was normalized to the control renilla luciferase
expression. Fireﬂy luciferase expression in the presence
of pBluescript (pBS) was set at 100% (Figure 3A).
A common pattern was observed in that most eﬃcient
inhibition was scored for the 19- and 23-nt siRNA
positioned at the 50-end of the original miRNA sequence,
which are the 19 and 23 variants of the D hairpin and the
190 and 23 variants of the E hairpin.
A similar trend was observed in HIV-1 inhibition
studies (Figure 3B). We co-transfected the HIV-1 mole-
cular clone LAI and the miRNA constructs into 293T cells
and virus production was measured as the CA-p24 level in
the culture supernatant at 2 days post-transfection. We
observed the strongest inhibition when the siRNA
inhibitor was situated at the 50-end of the miRNA
sequence. The optimized hairpins have a similar eﬃciency
of inhibiting HIV-1 production as the shRNA constructs
that were used as positive controls.
Based on these initial ﬁndings, we designed additional
miRNA constructs with 19–24nt antiviral sequences at the
50-end of the miRNA: A
pol47-24,A
pol47-19,B
pol1-22,B
pol1-19,
C
gag5-23,C
gag5-19’,E
ldr9-23 and E
ldr9-19’ (Table 1). Of the
original D
r/t5,D
ldr9 and E
r/t5 constructs, we selected
D
r/t5-19 because it is the best inhibitor. As a consequence,
the ldr9 inhibitor was introduced in the E hairpin. We
tested the eﬀectiveness of all new constructs against
luciferase reporters and HIV-1 (Table 1). The observed
inhibition is sequence-speciﬁc because non-matching
miRNAs did not have any eﬀect. Furthermore,
Antiviral miRNA polycistron
80 62 69 92 56 70 CMV pA
mir-17 mir-18 mir-19a mir-20 mir-19b
mir-17-19b polycistron
80 62 69 92 56 70
CMV pA
gag
pol
vif
vpr env
tat
rev
vpu
LTR
nef
LTR
ldr9
gag5
pol1 pol47 r/t5
A
B
Apol47 Cgag5 Bpol1 Dr/t5 Eldr9
Awt Cwt Bwt Dwt Ewt
mir-92
Figure 1. Schematic of the mir-17-92 cluster and design of the antiviral
miRNAs. (A) Genomic organization of the mir-17-92 polycistron
(upper panel) and predicted secondary structure of the mir-17-19b
transcript (A
wt-E
wt, lower panel). Mature miRNAs are indicated in red;
CMV, cytomegalovirus immediate early promoter; pA, SV40 poly-
adenylation signal. (B) Scheme of the HIV-1 proviral genome and
position of the target sequences (upper panel) used for the design of the
antiviral miRNA polycistron (lower panel). Guide strands of the
siRNA against HIV-1 are blue. Numbers between the pre-miRNAs
represent the length of the ﬂanks (in nucleotides). Original miRNA
names were replaced with the letters A–E and target genes are indicated
in superscript.
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Figure 2. Structure of the antiviral miRNAs based on pre-miRNAs D
wt and E
wt. Upper panel: The r/t5 and ldr9 siRNAs were incorporated into the
D
wt backbone, which produces the guide strand from the 50-side of the hairpin. The guide strand is marked in grey. We modiﬁed the passenger strand
to mimic structural features (mismatches, bulges and thermodynamic stability) of the natural pre-miRNA. The 19-nt antiviral siRNAs were
positioned either at the 50 (D
r/t5-19 and D
ldr9-19)o r3 0-end (D
r/t5-19’ and D
ldr9-19’) of the original miRNA and the length of the siRNAs
was extended at the 30-end to 23-nt (D
r/t5-23 and D
ldr9-23). Lower panel: The r/t5 siRNA was similarly incorporated into the E
wt pre-miRNA, which
produces the guide strand from the 30-side of the hairpin. The structure of the original shRNAs sh
r/t5 and sh
ldr9 are presented. HIV-1 sequences are
blue, mature wild-type miRNA sequences are red, pre-miRNA sequences are black, Watson–Crick base pairs are shown with dashes and G U
wobbles with dots.
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2816 Nucleic Acids Research, 2008, Vol. 36, No. 9the expression of the control renilla reporter was stable in
all experiments. The miRNA constructs with 19-nt anti-
HIV sequences showed a somewhat higher activity than
the extended versions. We therefore selected the 19-nt
inhibitors for the construction of antiviral miRNA
polycistrons. For simplicity, we removed the 19 indica-
tions from the miRNA names (e.g. A
pol47-19 becomes
A
pol47).
Expression andprocessing ofan antiviral miRNA
The original shRNA inhibitor sh
r/t5 seems slightly more
active than the optimized D
r/t5 miRNA molecule
(Figure 3). This could be due to the use of diﬀerent
promoters (polymerase III U6 versus polymerase II
CMV, respectively), but may also be due to diﬀerential
RNA processing eﬃciencies. We therefore wanted to
compare the siRNA level expressed from each construct.
We titrated 39–2500ng sh
r/t5 construct in 293T cells
and compared that with 2500ng D
r/t5 construct. Two
days post-transfection, total cellular RNA was isolated
from the transfected cells and analyzed on a Northern
blot with an r/t5 probe that detects the guide (antisense)
strand (Figure 4). The original D
wt hairpin was used as a
negative control. Quantiﬁcation of the RNA bands
showed that expression of the antiviral 19-nt siRNA by
construct D
r/t5 is about 15–30-fold lower than the
expression by construct sh
r/t5 (Figure 4, see numbers
below the blot). Although the siRNA expression level of
D
r/t5 is signiﬁcantly lower than that of sh
r/t5, the inhibitory
eﬀect measured in the luciferase and HIV-1 inhibition
assays is comparable. This result suggests that the intrinsic
inhibitory capacity of D
r/t5 is in fact much greater than
that of sh
r/t5.
Multimerization ofmiRNAs increases theinhibitory activity
To address the eﬀect of chaining of diﬀerent hairpins
for the silencing activity of the individual hairpins, we
coupled the A
pol47 inhibitor to wild-type pri-miRNAs.
We constructed two variants of A
pol47 with two or six
hairpins in a single transcript: A
pol47B
wt and A
pol47A
wt-E
wt
(A
wt-E
wt represents the complete wild-type mir-17-19b
polycistron). We tested the ability of these hairpins to
inhibit the Luc-A
pol47 reporter (Figure 5A, left). Fireﬂy
luciferase expression was normalized to the renilla
luciferase expression from the co-transfected pRL plas-
mid. We set the luciferase expression in the presence of
pBS at 100%. The knockdown eﬃciency of the single
A
pol47 hairpin was  40%, but chaining it with the B
wt
hairpin or the A
wt-E
wt cluster enhanced the silencing
activity. As a negative control, we included the A
wt-E
wt
construct. As a positive control, we included the original
shRNA. A similar pattern was observed for inhibition of
HIV-1 production (Figure 5A, right). Thus, expression of
a miRNA inhibitor as part of a miRNA polycistronic
transcript enhances the silencing activity.
Next, we constructed polycistronic hairpin constructs
with diﬀerent combinations of two, three or four hairpins
of the miRNA inhibitors A
pol47,B
pol1,C
gag5,D
r/t5 and
E
ldr9: AB, AC, AD, ACC, ACD, ACCD, ACDE and
ACDB
wt. We ﬁrst determined the knockdown eﬃciency of
each individual hairpin within the multiplex transcripts by
co-transfection with the corresponding luciferase reporter
into 293T cells (Figure 5B, Supplementary Table 2).
Constructs encoding the A
wt-E
wt cistron and individual
wild-type or non-matching miRNAs were used as negative
controls. For inhibitors A
pol47,C
gag5 and E
ldr9,w e
observed a remarkable enhancement of silencing activity
Table 1. Continued
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HIV-1 sequences are blue; pre-miRNA sequences are black; mature miRNA sequences are red; guide strand is bold;  , no; +, 10–30%; ++,
30–70%; +++, 70–100%; nd, not determined.
Nucleic Acids Research, 2008, Vol. 36, No. 9 2817when chained to other hairpins. For instance, construct
C
gag5 is poorly active compared to construct AC or ACDE
(Figure 5B). Construct B
pol1 does not exhibit any
inhibitory activity, either alone or when combined with
another hairpin as in AB. Since the B
pol1 hairpin structure
is rather unstable as predicted by the Mfold algorithm,
this could be due to misfolding of the hairpin RNA. We
therefore will not use hairpin B
pol1 in the ﬁnal polycistron
construct. Hairpin D
r/t5 does not beneﬁt from linkage to
other hairpins, but this is likely due to the high inhibitory
activity of the individual D
r/t5 inhibitor. Strong inhibition
of Luc-D
r/t5 was observed with D
r/t5, AD, ACD, ACCD
and ACDE, indicating that generation of eﬀective siRNAs
from the multiplex hairpin transcripts does not depend on
the miRNA position in the polycistron.
We further tested the ability of the antiviral miRNAs to
inhibit HIV-1 by co-transfection with the HIV-1 mole-
cular clone LAI (Figure 5C, Supplementary Table 2).
Consistent with the luciferase results, we observed a
moderate HIV-1 inhibition by the single miRNA con-
structs, except for construct B
pol1 (inactive) and D
r/t5
(highly active) (Figure 5C). Multimerization of the hair-
pins strongly enhanced the inhibition of HIV-1 produc-
tion, which is due both to enhancement of the silencing
activity of the individual hairpins and to the presence of
multiple antiviral siRNAs. The A
wt-E
wt construct was
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Figure 3. Inhibition of luciferase reporters and HIV-1 production by individual antiviral miRNAs. (A) Luciferase reporters (100ng) were
co-transfected in 293T cells with 20ng antiviral miRNA construct and 1ng pRL. The original shRNAs sh
r/t5 and sh
ldr9 were used as positive controls
and non-matching miRNAs as negative controls. Fireﬂy and renilla luciferase expression was measured 2 days post-transfection. Normalized ﬁreﬂy
luciferase expression in the presence of pBS was set at 100%. Mean values obtained in three independent experiments are shown ( SE). FL, ﬁreﬂy
luciferase; RL, renilla luciferase. (B) 239T cells were co-transfected with 150ng HIV-1 molecular clone LAI, 1ng pRL and 20ng of the indicated
antiviral miRNA constructs. sh
r/t5 and sh
ldr9 constructs were used as positive controls, D
wt and E
wt as negative controls. CA-p24 levels in the culture
supernatant and renilla luciferase expression were measured 2 days post-transfection. Normalized CA-p24 expression in the presence of pBS was set
at 100%. Error bars represent the standard deviation in four independent experiments.
2818 Nucleic Acids Research, 2008, Vol. 36, No. 9used as a negative control and the shRNA constructs were
used as positive controls.
Increased siRNA expression frompolycistronic miRNA
transcripts
We next performed Northern blot analysis of the antiviral
siRNAs made by the diﬀerent polycistron constructs
(Figure 6). The results are remarkably similar to the
activity data in Figure 5. For instance, siRNA expression
of A
pol47 is greatly increased by linkage to another hairpin
as in AD (Figure 6A). The Northern blot analysis of the
B
pol1 and the AB inhibitors provides an explanation for its
inactivity as only the  60-nt B
pol1 precursor is observed
(Figure 6B, indicated by an arrow). To study whether the
passenger siRNA strand of B
pol1 is made, we performed a
Northern blot analysis with the corresponding probe, but
failed to detect any passenger siRNAs (results not shown).
In contrast, properly processed siRNAs are produced
from hairpin A
pol47 in construct AB, indicating that the
inactive B unit in the two-hairpin transcript does not
negatively inﬂuence the active A unit (Figure 6A and B).
In addition, siRNA production from the A hairpin is
boosted for the polycistronic transcripts compared to the
single A
pol47 hairpin transcript. For inhibitor C
gag5,w e
also observed a strong increase in siRNA produc-
tion when the hairpin is combined with other hairpins in
a polycistronic transcript (Figure 6C). The D
r/t5 inhibitor
is expressed individually and does not beneﬁt from
chaining to other hairpins (Figure 6D), which correlates
nicely with the luciferase results (Figure 5B). For inhibitor
E
ldr9, we observed increased siRNA levels for ACDE
compared to the single hairpin (Figure 6E). The combined
luciferase inhibition results and the Northern blot analyses
demonstrate that the silencing activity of an individual
hairpin RNA can be signiﬁcantly enhanced when
expressed in a polycistronic transcript.
HIV-1 replication is suppressed in cells stablyexpressing
an antiviralmiRNA polycistron
We next created stably transduced SupT1 cells with a
lentiviral vector (pLV) expressing the individual miRNA
constructs A
pol47,B
pol1,C
gag5,D
r/t5,E
ldr9 and the
polycistronic ACDE construct. pLV expressing the con-
trol miRNA N (Invitrogen) was used as negative control.
To study the impact of the antiviral miRNAs on SupT1
cell viability, we set up a sensitive toxicity screen for cells
transduced with N, A
pol47 and ACDE. We cultured the
cells for 36 days after lentiviral transduction and followed
the percentage of GFP+ (transduced) and GFP-
(untransduced) cells by FACS (Table 2). We did not
observe a decrease in the fraction of transduced cells,
indicating a similar growth rate as untransduced cells.
The stably transduced SupT1 cells were selected by
FACS sorting and subsequently infected with HIV-1
(0.5ng of CA-p24). Virus replication was followed for 7
days by measuring the CA-p24 level in the culture
supernatant. Fast virus replication and virus-induced
cytopathic eﬀects were observed in cells expressing
miRNAs N, B
pol1,C
gag5 and untransduced SupT1 cells
(Figure 7). HIV-1 replication was inhibited by the
individual hairpins A
pol47,D
r/t5 and E
ldr9. Virus replica-
tion was profoundly inhibited in SupT1 cells expressing
the polycistronic miRNA construct ACDE and control
cells that express an extended triple shRNA construct
(e-shRNA 3) (manuscript in preparation).
DISCUSSION
In this study, we designed a combinatorial RNAi
approach against HIV-1 using the human mir-17-92
polycistron. We ﬁrst constructed individual pri-miRNA
transcripts against ﬁve conserved regions of HIV-1 under
the control of a CMV promoter. We maintained the
secondary structure of the original pre-miRNAs and
included the single-stranded ﬂanks because these are
important for proper miRNA processing and subsequent
RISC loading (12). We used the CMV promoter to express
the transcripts because most primary miRNAs are
transcribed by RNA polymerase II (7), which also
allows inducible or tissue-speciﬁc miRNA expression
(22,53,54). Previously, several reports have demonstrated
eﬀective gene knockdown in mammalian cells with
siRNAs derived from miRNA precursors (17,18,22,53).
However, none of these studies addressed the issue that a
mature miRNA is typically 22–24nt, whereas an siRNA
is only 19-nt in length. Here, we demonstrate that
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Figure 5. Inhibition of luciferase reporters and HIV-1 production by antiviral polycistronic miRNAs. (A) Knockdown eﬃciencies of the antiviral
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pol47,A
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wt and A
pol47A
wt-E
wt. Left panel: 293T cells were co-transfected with
100ng Luc-A
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post-transfection, CA-p24 levels in the culture supernatant and renilla luciferase expression were measured. Normalized CA-p24 level in the absence
of inhibitor was set at 100%. Mean values obtained in four independent experiments are shown ( SE).
2820 Nucleic Acids Research, 2008, Vol. 36, No. 9positioning of 19–24nt antiviral siRNA sequences at the
50-end of the pre-miRNA hairpin stem results in optimal
HIV-1 inhibition.
Despite the optimization of the miRNA-like inhibitors,
their activity is less than that of the original shRNA
antivirals that were used to design the miRNAs. We
therefore addressed whether the miRNA-like inhibitor is
correctly processed and compared the amount of siRNA
produced from the miRNA versus shRNA constructs. The
siRNA level produced by the shRNA construct sh
r/t5 is
15–30-fold higher than the D
r/t5 miRNA, which is likely
due to the use of diﬀerent promoters (RNA polymerase III
versus RNA polymerase II). Interestingly, the shRNA
inhibitor did only show marginally higher inhibitory
activity, suggesting that the intrinsic inhibitory activity
of the miRNA-like inhibitor is in fact much greater than
the shRNA variant. Consistent with these results, vectors
encoding hairpin structures that closely resemble a natural
pre-miRNA produced  12-fold more mature siRNAs
than vectors encoding simple hairpin structures (21). The
superior activity of natural miRNA-like inhibitors is likely
attributed by the intrinsic properties of a miRNA, which is
processed in the nucleus by Drosha, exported to the
cytoplasm, processed further by Dicer and loaded into
RISC. In the case of an shRNA, the Drosha step is
bypassed, which could provide a less-eﬃcient entry into
the RNAi pathway.
Moderate HIV-1 inhibitory activity was observed with
constructs expressing a single miRNA hairpin. Interest-
ingly, we demonstrate that co-expression of two or
more hairpins in a single transcript greatly enhanced
the silencing activity of each individual hairpin in the
transcript. Northern blot analyses showed that the
increased inhibitory activity correlates with higher
siRNA expression levels. Multimerization of diﬀerent
miRNA hairpins is of particular interest for targeting of
RNA viruses such as HIV-1 and HCV because of their
extreme genetic diversity and potential for mutational
escape. Two recent papers presented the potential of
combinatorial RNAi using two miRNA-30 hairpins
(55,56). In agreement with these studies, we showed an
increase in RNAi activity upon multimerization of 2, 3, 4
or 6 hairpins in a single transcript. Another study used the
miR-30 backbone to multiplex artiﬁcial miRNAs and
reported decreased RNAi activity for the tandem plasmid,
which may be due to miRNA processing problems (57).
Thus, chaining of miRNAs needs a very careful transcript
design. Most studies have used either the miR-30 or
miR-155 backbone because these molecules have been
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Figure 6. Northern blot analyses of siRNAs derived from antiviral
miRNA constructs. 293T cells were transfected with the indicated 1, 2,
3 and 4 antiviral miRNA constructs and siRNAs were detected in total
cellular RNA using 19-nt complementary LNA oligonucleotide probes.
Diﬀerent miRNA transcripts were analysed: (A)A
pol47,( B)B
pol1,
(C)C
gag5,( D)D
r/t5 and (E)E
ldr9. As negative controls, pBS or miRNA
constructs targeting another gene were used. The original shRNA
constructs were used as positive controls, showing the mature siRNAs.
Ethidium bromide staining of 5S rRNA serves as sample loading
control. M, RNA size marker (nt) is shown on the left, the probe used,
is shown on the right.
Table 2. Toxicity screen of antiviral miRNA constructs
Construct Percentage of GFP+cells after transduction
Day 0 Day 4 Day 20 Day 36
pLV 0 0 0 0
N 2.8 3 1.5 4.5
A
pol47 666 4 . 8
ACDE 2.4 3 1.5 2.9
Nucleic Acids Research, 2008, Vol. 36, No. 9 2821studied extensively. Our study focuses on the natural mir-
17-92 polycistron and we demonstrate that insertion of
four antiviral siRNAs creates a transcript that is properly
processed into functional antiviral miRNAs that eﬀec-
tively inhibit HIV-1 production and replication.
A major concern of the miRNA approach is the oﬀ-
target eﬀect on cellular transcripts with partial sequence
complementarity. Such an oﬀ-target eﬀect may require
only a complementarity of 6–8nt between the seed region
of the miRNA and the target (58,59). Such a weak
restraint results in numerous potential oﬀ-target genes for
any miRNA. When multiple miRNAs are used, the
number of potential oﬀ-targets will increase, increasing
the chance of a negative eﬀect on the treated cells.
However, we observed no obvious cellular changes in a
sensitive toxicity screen. Furthermore, the observed
inhibition of ﬁreﬂy luciferase reporters clearly showed
sequence-speciﬁcity as non-matching miRNAs did not
have any eﬀect and the expression of the control renilla
reporter was not aﬀected. Another study, in which
artiﬁcial miRNAs were expressed in Arabidopsis thaliana,
conferred viral resistance without cellular alterations,
suggesting that oﬀ-target eﬀects are not signiﬁcant (60).
Furthermore, recently evidence emerges that siRNA
sequences inserted in a miRNA backbone do not compete
for transport and incorporation into RISC, while compe-
tition was observed when the same siRNA sequences
were presented as synthetic siRNAs or shRNAs (61).
Nonetheless, oﬀ-targeting is a genuine concern for the
development of any RNAi-based gene therapy against
HIV-1 and the potential risk should be assessed properly
in relevant in vivo models prior to an eventual clinical
application (62).
We have shown in stably transduced T-cell lines that
multiple eﬀective miRNAs inhibit HIV-1 replication much
stronger than a single miRNA. These data, together with
our previous shRNA studies (32,63), indicate that a
combinatorial RNAi approach against HIV-1 results in
an increased magnitude of inhibition and consequently a
restriction of viral escape. Current strategies combine
multiple polymerase III shRNA expression cassettes (63),
which results in high expression levels. This may not
always be desired in a gene therapy setting because of
increased toxicity due to saturation of the RNAi
machinery with siRNAs (46). The use of polymerase II
promoters to express the miRNA polycistron will reduce
this risk because of lower expression levels. In addition,
polymerase II cassettes allow expression in a tissue-speciﬁc
manner and inducible gene expression, which increases the
ﬂexibity for gene therapy and functional genomic applica-
tions (22,54).
For HIV-1 gene therapy applications the use of a
hematopoietic or T-cell-speciﬁc promoter can increase the
target cell speciﬁcity. An interesting candidate is the WAS
promoter that is active in human hematopoietic precursor
cells (CD34+) and T lymphocytes, B cells and dendritic
cells (64). Another intriguing possibility is to use the
HIV-1 LTR promoter to express the miRNA polycistron.
Transcriptional activation of the HIV-1 LTR requires the
viral Tat protein, which is produced only in HIV-
1-infected cells, thereby allowing exquisite target cell
speciﬁcity. This approach has previously been employed
for shRNA expression (65). Thus, several approaches can
be tested experimentally in order to optimize the antiviral
miRNA polycistron strategy for HIV-1 inhibition.
In summary, one can eﬀectively combat HIV-1 with
multiple miRNA eﬀector molecules transcribed from a
single polycistronic transcript. We showed that expression
of the miRNA polycistron results in the production of
functional mature miRNAs that can eﬃciently and
selectively inhibit HIV-1. Further optimization of this
construct by increasing the target cell speciﬁcity and
inducibility will be a further step towards a gene
therapeutic approach against HIV-1.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
HIV-1 RNA research in the Berkhoutlab is sponsored by
ZonMw (VICI grant) and NWO-CW (TOP grant). We
thank Stephan Heynen for performing CA-p24 ELISA
and Jens Gruber for useful discussions. Funding to pay
the Open Access publication charges for this article was
provided by ZonMw and NWO-CW.
Conﬂict of interest statement. None declared.
C
A
-
p
2
4
 
(
n
g
/
m
l
)
2468
Apol47
Dr/t5
Bpol1
ACDE e-shRNA3
days post-infection
0
6
12
9
3
15
N –
Eldr9
Cgag5
0
Figure 7. Inhibition of HIV-1 replication in SupT1 cells transduced
with lentiviral vectors expressing antiviral miRNAs A
pol47,B
pol1,C
gag5,
D
r/t5,E
ldr9 and ACDE. Untransduced SupT1 cells and cells transduced
with the unrelated miRNA N were used as negative controls. Cells
expressing an extended triple shRNA construct (e-shRNA 3) serve as
positive control. SupT1 cells stably expressing miRNAs A
pol47,B
pol1,
C
gag5,D
r/t5,E
ldr9 and ACDE were infected with HIV-1 and virus
replication was monitored for 7 days by measuring CA-p24 in the
culture supernatant. One representative experiment is shown, similar
results were obtained in three independent experiments.
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